{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:25:14Z","timestamp":1793946314026,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010373","name":"Stichting Blinden-Penning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010302","name":"Algemene Nederlandse Vereniging ter voorkoming van Blindheid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010318","name":"Landelijke Stichting voor Blinden en Slechtzienden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010331","name":"Stichting voor Ooglijders","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010326","name":"Stichting A.F. Deutman Oogheelkunde Researchfonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010330","name":"Stichting Retina Fonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010374","name":"Stichting Blindenhulp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010372","name":"Rotterdamse Stichting Blindenbelangen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010372","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ajo.2026.03.016","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:58:46Z","timestamp":1773680326000},"page":"34-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-Term Follow-Up of PLACE and SPECTRA Trials: Outcomes After Successful and Unsuccessful Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy"],"prefix":"10.1016","volume":"287","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0583-2450","authenticated-orcid":false,"given":"Femke M.","family":"van den Tillaart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Chang-Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3106-0455","authenticated-orcid":false,"given":"Helena M.A.","family":"Feenstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9589-602X","authenticated-orcid":false,"given":"Thomas J.","family":"van Rijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel B.","family":"Hoyng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roselie M.H.","family":"Diederen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier O.","family":"Schlingemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6737-7932","authenticated-orcid":false,"given":"Camiel J.F.","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Yzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elon H.C.","family":"van Dijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2026.03.016_bib0001","article-title":"Pachychoroid disease: review and update","author":"Cheung","year":"2024","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ajo.2026.03.016_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100973","article-title":"Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders","volume":"86","author":"Spaide","year":"2022","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajo.2026.03.016_bib0003","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/OPTH.S115685","article-title":"Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life","volume":"11","author":"Breukink","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2026.03.016_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2024.101236","article-title":"Central serous chorioretinopathy: an evidence-based treatment guideline","volume":"101","author":"Feenstra","year":"2024","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"10.1016\/j.ajo.2026.03.016_bib0005","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.oret.2023.10.024","article-title":"Comparing half-dose photodynamic therapy with subthreshold micropulse laser for the treatment of Central serous chorioretinopathy","volume":"8","author":"Brelen","year":"2024","journal-title":"Ophthalmol Retina"},{"issue":"12","key":"10.1016\/j.ajo.2026.03.016_bib0006","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/bjophthalmol-2017-311291","article-title":"Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group","volume":"102","author":"Roca","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2026.03.016_bib0007","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.survophthal.2023.03.001","article-title":"Comparing interventions for chronic central serous chorioretinopathy: a network meta-analysis","volume":"68","author":"You","year":"2023","journal-title":"Surv Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2026.03.016_bib0008","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","article-title":"Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the place trial","volume":"125","author":"van Dijk","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.03.016_bib0009","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ajo.2021.06.020","article-title":"Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (spectra): a randomized controlled trial","volume":"233","author":"van Rijssen","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2026.03.016_bib0010","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ajo.2016.07.026","article-title":"A multicenter study on the long-term outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy","volume":"170","author":"Lai","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2026.03.016_bib0011","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/IAE.0b013e3182670fbe","article-title":"Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study","volume":"33","author":"Silva","year":"2013","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ajo.2026.03.016_bib0012","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/IAE.0000000000003686","article-title":"Increasing evidence for the safety of fovea-involving half-dose photodynamic therapy for chronic central serous chorioretinopathy","volume":"43","author":"Feenstra","year":"2023","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.ajo.2026.03.016_bib0013","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00417-018-4003-z","article-title":"Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy","volume":"256","author":"van Rijssen","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2026.03.016_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181479","article-title":"Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: a 3-year follow-up study","volume":"12","author":"Haga","year":"2017","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ajo.2026.03.016_bib0015","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3928\/23258160-20191119-03","article-title":"Long-term efficacy and safety of photodynamic therapy in patients with chronic central serous chorioretinopathy","volume":"50","author":"Park","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.ajo.2026.03.016_bib0016","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2020.04.007","article-title":"Crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy: the REPLACE trial","volume":"216","author":"van Rijssen","year":"2020","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2026.03.016_bib0017","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00417-022-05836-x","article-title":"Long-term follow-up of chronic central serous chorioretinopathy patients after primary treatment of oral eplerenone or half-dose photodynamic therapy and crossover treatment: SPECTRA trial report No. 3","volume":"261","author":"Feenstra","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2026.03.016_bib0018","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3190136","article-title":"Long-term effects of half-time photodynamic therapy on retinal sensitivity in eyes with chronic central serous chorioretinopathy","volume":"2020","author":"Iwase","year":"2020","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.ajo.2026.03.016_bib0019","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ophtha.2014.09.034","article-title":"One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy","volume":"122","author":"Fujita","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.03.016_bib0020","first-page":"T8","article-title":"Long-term outcome of half-dose verteporfin photodynamic therapy for the treatment of central serous chorioretinopathy (An American Ophthalmological Society Thesis)","volume":"113","author":"Lai","year":"2015","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"4","key":"10.1016\/j.ajo.2026.03.016_bib0023","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41433-022-02044-z","article-title":"Longitudinal follow-up and outcome analysis in central serous chorioretinopathy","volume":"37","author":"Sahoo","year":"2023","journal-title":"Eye"},{"issue":"10","key":"10.1016\/j.ajo.2026.03.016_bib0024","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1038\/s41433-020-01345-5","article-title":"OCTA evaluation of treatment-na\u00efve flat irregular PED (FIPED)-associated CNV in chronic central serous chorioretinopathy before and after half-dose PDT","volume":"35","author":"Guo","year":"2021","journal-title":"Eye (Lond)"},{"issue":"10","key":"10.1016\/j.ajo.2026.03.016_bib0025","doi-asserted-by":"crossref","first-page":"6886","DOI":"10.1167\/iovs.13-11665","article-title":"Functional characterization and multimodal imaging of treatment-naive \"quiescent\" choroidal neovascularization","volume":"54","author":"Querques","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2026.03.016_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101113","article-title":"Towards a better understanding of non-exudative choroidal and macular neovascularization","volume":"92","author":"Sacconi","year":"2023","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajo.2026.03.016_bib0027","doi-asserted-by":"crossref","DOI":"10.1111\/aos.17507","article-title":"Outcome and safety of multiple photodynamic therapy sessions in chronic central serous chorioretinopathy","author":"Chang-Wolf","year":"2025","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ajo.2026.03.016_bib0028","doi-asserted-by":"crossref","DOI":"10.1111\/aos.17511","article-title":"Effectiveness and safety of repeated photodynamic therapy in recurrent central serous chorioretinopathy","author":"van den Tillaart","year":"2025","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2026.03.016_bib0029","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.oret.2020.07.026","article-title":"Multimodal imaging-based central serous chorioretinopathy classification","volume":"4","author":"Chhablani","year":"2020","journal-title":"Ophthalmol Retina"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426001376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426001376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:27:16Z","timestamp":1793942836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426001376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"alternative-id":["S0002939426001376"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.03.016","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Follow-Up of PLACE and SPECTRA Trials: Outcomes After Successful and Unsuccessful Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}